Skip to content

An effect of nacetycystine in Hepatitis A positive children aged 5yr to 15 yrs:A randomized controlled trial

AN EFFECT OF N-ACETYLCYSTEINE IN HEPATITIS A POSITIVE CHILDREN AGED 5 YEARS TO 15 YEARS: A RANDOMIZED CONTROLLED TRIAL - Nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/110203
Enrollment
50
Registered
2026-05-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B159- Hepatitis A without hepatic coma

Interventions

Intervention1: Nacetycystine: NAC will be given intravenously as 21-hour regimen in 3 doses with cumulative dose of 300 mg/kg over 21 hours (initial loading dose of 150 mg/kg over one hour, followed b

Sponsors

Dr Dheeraj Dasariya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Aged between 5to 15 years Parents willing to participate in the study Hepatitis A virus antibody +ve serology

Exclusion criteria

Exclusion criteria: Aged more than 16 years Prior history of NAC administration Wilson disease Drug induced hepatitis

Design outcomes

Primary

MeasureTime frame
Change in serum ALT levels from baseline (Day 0) to Day 7 after initiation of N-acetylcysteine therapy in children aged 5 15 years with hepatitis A.Timepoint: 7 days

Secondary

MeasureTime frame
Time in days to normalization of serum ALT,AST Levels assessed from day 0 to day 14 or dischargeTimepoint: 14 day

Countries

India

Contacts

Public ContactDr Ghanshyam Das
drghanshyamh@gmail.com919826279678

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026